Wortmannin (KY 12420)

目录号:S2758 别名: SL-2052, BRN 0067676, NSC 627609 中文名称:渥曼青霉素

仅限科研使用

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609)是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。

Wortmannin (KY 12420) Chemical Structure

CAS: 19545-26-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1441.24 现货
RMB 899.84 现货
RMB 3661.18 现货
大包装
大剂量询单

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Wortmannin (KY 12420)发表文献263篇:

产品安全说明书

PI3K抑制剂选择性比较

相关PI3K产品

生物活性

产品描述 Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609)是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。
靶点
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
体外研究

钙或肽底物不影响Wortmannin对MLCK的抑制,但高浓度的ATP会减弱此种抑制。Wortmannin直接与MLCK催化结构域相互作用,导致不可逆转的酶活性减弱。Wortmannin对cAMP依赖蛋白激酶,cGMP依赖的蛋白激酶,钙调蛋白依赖激酶II,和蛋白激酶C均无抑制作用。[1] Wortmannin抑制由fMLP诱导的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50为5 nM 。在人中性粒细胞中,Wortmannin剂量为100 nM时可发挥完全抑制作用,增加PtdInsP2水平,且对PtdInsP和 PtdIns没有影响;Wortmannin可动态调控F-actin水平对fMLP刺激的肌动蛋白聚合无影响。[2]在RBL-2H3细胞中,Wortmannin通过结合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50为3 nM)对,对Pi4-kinase没有影响。Wortmannin也抑制Fc epsilon RI介导的组胺分泌和白三烯释放,对酪氨酸激酶Lyn无影响。[3]在大鼠脂肪细胞中,剂量为0.1 μM的 Wortmannin可完全抑制胰岛素诱导的己糖吸收,二不影响异丙肾上腺素刺激的脂肪分解活性。[4] 在人脐静脉内皮细胞中,在IGF-1的存在下,Wortmannin抑制胰岛素诱导一氧化氮生产,IC50为500nM。[5]在中国仓鼠卵巢细胞中, Wortmannin以50 μM剂量可抑制DNA双链断裂(DSB)修复,但对DSB水平无影响或单链断裂(SSB)酶活无影响。Wortmannin可加强电离辐射(红外)诱导的细胞毒作用,但本身无毒性。[6] Wortmannin抑制水球样激酶(PLK 1)活性,IC 50为24nM,造成细胞G 2 / M阻滞。[7] 在人巨噬细胞中,Wortmannin增加 Toll样受体(TLR)介导的白细胞介素- 6的积累,EC 50 = 50 nM。在小鼠巨噬细胞中,Wortmannin显着增强TLR诱导一氧化氮合酶(iNOS)的表达和亚硝酸盐积累。Wortmannin激活核因子-κB和上调细胞因子mRNA量。[8] Wortmannin也抑制水球样激酶(PlK)1和PlK 3,在有丝分裂中发挥重要作用。Wortmannin治疗可能导致可减少由DNA损伤诱导的p53丝氨酸20位磷酸化。[9] 在SW 1990细胞中,Wortmannin可抑制透明质酸诱导Akt磷酸化和细胞运动/迁移。[10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor2Nk42KM7:TR?= Mnf5NU01KGR? NFf2UIZFVVOR MnXv[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> M3nLeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEmwN|g{Lz5{NUS5NFM5OzxxYU6=
H1703 NYn6c|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTvUnE3Oi53IN88US=> MWGxMVQh\A>? NYnKTW5xTE2VTx?= M1[xcYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv MonsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUCzPFMoRjJ3NEmwN|g{RC:jPh?=
HUVECs M3H0OWN6fG:2b4jpZ4l1gSCDc4PhfS=> Mn;kNVAxKG6P NHn0cHozPCCq M4XVTIF1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR3MEG4Okc,OjV2NUCxPFY9N2F-
APRE-19 NVjDWXdpSXCxcITvd4l{KEG|c3H5 NVTSTohZPSEQvF2= NGrhTmszPCCq MVPhZo9tcXOqZYOgSmxbNW2nZHnheIVlKHC{bz3zeZJ3cX[jbD;hcpRqNWGyb4D0c5NqeyCjY4Tpeol1gQ>? NWLuW5BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNlk3OTdpPkK1N|I6PjF5PD;hQi=>
MDA-MB-231 MXnBdI9xfG:|aYOgRZN{[Xl? NYPtSJAyOcLizszNxsA> NFTjVHI1QCCq MluwSG1UVw>? Momx[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJJRz\WG2ZXSge4l1cCB{NTFOwG0hd2ZiRkGgc5IhTjJiwrC= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyMEmzNkc,OjV|MEC5N|I9N2F-
MCF7 NX3Mco9ETnWwY4Tpc44hSXO|YYm= NXvtb5BuOTByIH7N NUP6PFF6OjRiaB?= NXrxdo1I\WyrbXnuZZRmeyCHMj3pcoR2[2WmIFHSSU1NfWNiYXP0bZZqfHl? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkW1O{c,OjVzN{K1OVc9N2F-
HT-29  M2CzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojUNU42yqEEtV2= M3PEVFk3KGh? MU\k[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D NIjic5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxNlEzOyd-MkWwNVIyOjN:L3G+
MO59K  M{TmeWN6fG:2b4jpZ4l1gSCDc4PhfS=> MlXOOeKh|ryP MnTLO{Bl MknBSG1UVw>? MYHlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MmHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUO1OlEoRjJ2OUWzOVYyRC:jPh?=
MO59J M4jXN2N6fG:2b4jpZ4l1gSCDc4PhfS=> NXnWS3U5PcLizszN M2\k[|ch\A>? NE\6dGJFVVOR MkTU[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NFK5dFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1N|U3OSd-MkS5OVM2PjF:L3G+
MO59K  NI\n[5NCeG:ydH;zbZMhSXO|YYm= NXjsOotmOTBizszN NVPncm5iOjRiaB?= MlK5SG1UVw>? MmDibY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3M{W2NUc,OjR7NUO1OlE9N2F-
MO59J M1jV[WFxd3C2b4Ppd{BCe3OjeR?= Mn7WNVAh|ryP Mn\tNlQhcA>? Mn7sSG1UVw>? NUm2fXVmcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUO1OlEoRjJ2OUWzOVYyRC:jPh?=
HepG2 NITMXJZHfW6ldHnvckBCe3OjeR?= NUi4XnViOTByIH7N MoHSNE42KGh? M3vyXGROW09? M3fGWYJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> M4HsU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[zN|UxLz5{NEi2N|M2ODxxYU6=
A549  NVjq[m9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r2blMhyrWPwrC= NV:0dXZ4OiCq NX:3N|Vye3WycILld5NmeyCyZX3leJJmgGWmLXnu[JVk\WRiQXv0JIFv\CCJU1uz{tIh[WO2aY\heIlwdixiUz3wbIF{\SCjcoLld5QtKGOnbHygZZBweHSxc3nzJIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbh?= NFHJd5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi0O|g3Oyd-MkS4OFc5PjN:L3G+
A549  MWXGeY5kfGmxbjDBd5NigQ>? M4DuTlExyqEQvH5CpC=> MofpNVYhcA>? MUTEUXNQ NHHCTnhud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> NIXDTZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwNlEyOSd-MkS4NFIyOTF:L3G+
SK-N-LO MnzLSpVv[3Srb36gRZN{[Xl? M37jN|ExOCCwTR?= MWCwMlUhcA>? Mlfq[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v NIDnfG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1OFYxPid-MkS2OVQ3ODZ:L3G+
HL-60 NHrRWlNHfW6ldHnvckBCe3OjeR?= NWPqcnpDOC5zwrFOwG0> NHmwNYE4OiCq M4TZR4Jtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> M4ru[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkC3Nlc{Lz5{NE[wO|I4OzxxYU6=
HepG2  MnK4SpVv[3Srb36gRZN{[Xl? NYjZVItuOjByIH7N MXewMlUhcA>? NUPRc3o1[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= NHixUYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzOVE6Oid-MkS1N|UyQTJ:L3G+
H520 M3u1W2Z2dmO2aX;uJGF{e2G7 NFXxN2gyOMLizszN NHLZRWMyKGh? M{TZWGROW09? NXr4dFVj\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ NUXmeo1xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OFc6OzVpPkK0OFQ4QTN3PD;hQi=>
H1975 NHfCUGdHfW6ldHnvckBCe3OjeR?= NH3YR2kyOMLizszN M4\DfFEhcA>? MoTrSG1UVw>? MnzD[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR2N{mzOUc,OjR2NEe5N|U9N2F-
MG-63 NHOyTmFCeG:ydH;zbZMhSXO|YYm= MW[xNEDDvU1? M2jJTVEzKGh? MXPlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHrpeVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PFMxOSd-MkSzOVg{ODF:L3G+
5637 MYHBdI9xfG:|aYOgRZN{[Xl? NVfyN2ExOTEEoN88US=> NWK4SJo5PDBibXnu MkX1doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv NF\LbWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|g3QCd-MkSzN|M5Pjh:L3G+
HEK-293 NX\6b4lSTnWwY4Tpc44hSXO|YYm= MnPoNVUxdk1? M4r2NlE3KGh? MVfEUXNQ Mn64[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? NVSyd5BjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQ{PjZpPkK0N|I1OzZ4PD;hQi=>
SW480  NF3SPYpHfW6ldHnvckBCe3OjeR?= NY\6V2lxOTVybl2= MnL1NlAhcA>? NUTuTYpuTE2VTx?= NFjhPGhz\WS3Y3XzJINmdGy3bHHyJIFk[3WvdXzheIlwdiCxZjFOtk1k[XSnbnnu MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkSzOlYoRjJ2M{K0N|Y3RC:jPh?=
HepG2 NG\LRVRHfW6ldHnvckBCe3OjeR?= NInNTIIyODBibl2= NVnPdWdxOjRiaB?= MYPheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NVAoRjJ2Mkm3OVExRC:jPh?=
HCT 116  MoG5SpVv[3Srb36gRZN{[Xl? Mn;0NVAxKG6P Ml3zNlQhcA>? NELLSm9ifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= NUGzeXhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc2OTBpPkK0Nlk4PTFyPD;hQi=>
BEL/FU M{TZWmZ2dmO2aX;uJGF{e2G7 M4HzUlEhdU1? MVSyOEBp MVHk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> M2iwc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkOyNFk6Lz5{NEKzNlA6QTxxYU6=
Huh7  M4fHN2Z2dmO2aX;uJGF{e2G7 M{fuZ|PDqM7:TR?= M3ThVVEhcA>? MmjYdoVlfWOnczD0bIUhfmm{dYOg[Y51enliaX70c{B1cGViY3XscJM> M4Lj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi0NVk3Lz5{NEG4OFE6PjxxYU6=
A-375 MoK2RZBweHSxc3nzJGF{e2G7 M3XvPFQwQCEQvF2= M1iwSlI1KGh? M2HBSoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MoPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUOxO|MoRjJ2MUGzNVc{RC:jPh?=
A-375-TS  NYjEU402SXCxcITvd4l{KEG|c3H5 MX20M|gh|ryP NGKxco8zPCCq NVjFbJRX\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NGD3elI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxN|E4Oyd-MkSxNVMyPzN:L3G+
Mel-HO MW\BdI9xfG:|aYOgRZN{[Xl? MWm0M|gh|ryP NHOwNpMzPCCq MXzlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NEnW[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxN|E4Oyd-MkSxNVMyPzN:L3G+
Mel-HO-TS MWnBdI9xfG:|aYOgRZN{[Xl? NXvXPIt1PC96IN88US=> MXKyOEBp M2D4fIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NEDlXYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxN|E4Oyd-MkSxNVMyPzN:L3G+
MeWo NU\4bGd1SXCxcITvd4l{KEG|c3H5 MkmyOE85KM7:TR?= NGDTXIgzPCCq NH\0cYJmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUOxO|MoRjJ2MUGzNVc{RC:jPh?=
Mel-2a MYXBdI9xfG:|aYOgRZN{[Xl? NYPwVmtpPC96IN88US=> NHzIdoEzPCCq NGD4PG9mdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg M4TJSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzNVc{Lz5{NEGxN|E4OzxxYU6=
MDA-MB-231 MnXYSpVv[3Srb36gRZN{[Xl? NXLhWIVMOOLCk{SwNEBvVQ>? NGS4SVQ1KGh? MmfQd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NU\TV5Q4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NFYzPTlpPkKyPVA3OjV7PD;hQi=>
MDA-MB-231 MUnGeY5kfGmxbjDBd5NigQ>? MorTOFAxKG6P MoDROEBp MYPk[YNz\WG|ZYOgUW1RNTliYX7kJGlNNThicILveIVqdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjlyNkK1PUc,OjJ7ME[yOVk9N2F-
Jurkat NXT2Z2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:wMlI2NTFwMkWg{txO MUeyOE81QCCq MlXZSG1UVw>? MVLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NGLyWo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1O|E5PSd-MUm3OVcyQDV:L3G+
Namalwa NVfIU|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvZnVtOC5{NT2xMlI2KM7:TR?= Mn3rNlQwPDhiaB?= MWjEUXNQ Mn7JbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NEf1bYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1O|E5PSd-MUm3OVcyQDV:L3G+
Jurkat Mnj1RZBweHSxc3nzJGF{e2G7 M4rGT|AvOjVvMT6yOUDPxE1? NFS3VYozPC92ODDo M1;sS2ROW09? NXfmWmdzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NVLKcJN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVcyQDVpPkG5O|U4OTh3PD;hQi=>
Namalwa NXnORVM2SXCxcITvd4l{KEG|c3H5 M2mxb|AvOjVvMT6yOUDPxE1? MXOyOE81QCCq NWrMSZp{TE2VTx?= M4D3Wolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3N{G4OUc,OTl5NUexPFU9N2F-
K562 M4PEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzMNlQhcA>? M4W2NWlEPTB;MkZCtVAvOTRibl2= M{fKN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Nk[yN|YyLz5zOU[2NlM3OTxxYU6=
SW1990 NFfWTZZHfW6ldHnvckBCe3OjeR?= MnHnNE4xOS1zIN88US=> M3y3ZlEhcA>? M4\yUIlvcGmkaYTzJGhCNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NWLjcoVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlkxOjBpPkG5OFY6ODJyPD;hQi=>
RT112  NUL4bIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLNVDDqM7:TR?= M4LSNlI1KGh? NEf3fmVFVVOR NFHwZmFl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? Mo\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5OEe4N|IoRjF6N{i3PFMzRC:jPh?=
MHG-U1 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3wPJpDOTEEoN88US=> MoPpNlQhcA>? NVKwT|dlTE2VTx?= NHTlOZdl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NVzkVW9wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3PFc5OzJpPkG4O|g4QDN{PD;hQi=>
SMMC-7721 MnLERZBweHSxc3nzJGF{e2G7 M{TtOFIxOMLibl2= NIi4N3gzPCCq MW\pcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ NHrueGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1O|E6OSd-MUe1OVcyQTF:L3G+
SMMC-7721 M{XwPWZ2dmO2aX;uJGF{e2G7 M3zEelIxOMLibl2= NH34eIIzPCCq NYLDdW0zfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3N{G5NUc,OTd3NUexPVE9N2F-
HeLa NFP3XpBHfW6ldHnvckBCe3OjeR?= NIjDcnkyODEEoH7NxsA> Ml71NUBp NX\jN5c4[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> NWHhdFVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4PVA6OTVpPkG2PFkxQTF3PD;hQi=>
MRC5VI M{Hwb2Z2dmO2aX;uJGF{e2G7 MYmxNk42KG2P NH\yc5QxNjViaB?= M2m3SmROW09? NXr1VIJW[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ{MkezPVQoRjF4MkK3N|k1RC:jPh?=
AT5BIVA M3LHcmZ2dmO2aX;uJGF{e2G7 M2DVdVEzNjVibV2= NWniW4ZmOC53IHi= MYXEUXNQ MWPhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M2SzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4MkK3N|k1Lz5zNkKyO|M6PDxxYU6=
M059J NYPYZWRYTnWwY4Tpc44hSXO|YYm= MVWxNk42KG2P NHXlcnUxNjViaB?= MnnkSG1UVw>? MVrhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NYn0PYRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[yNlc{QTRpPkG2NlI4Ozl2PD;hQi=>
HeLa M3vYSmZ2dmO2aX;uJGF{e2G7 M1LFe|EzNjVibV2= NIXL[YcxNjViaB?= NGGyPYZFVVOR M1OxU4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjJ{N{O5OEc,OTZ{MkezPVQ9N2F-
N2a NVnLVIRNSXCxcITvd4l{KEG|c3H5 NGfJOZMxNjFvMUCg{txO MlvpNkBp M3WyRYlv\HWlZYOg[IVkemWjc3XkJINmdGxidnnhZoltcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh2Mke2O{c,OTV6NEK3Olc9N2F-
Jurkat  NFf2THdMcW6jc3WgRZN{[Xl? MoDRTWM2OCCxZjCyOEBvVQ>? NYDFR|ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OlQ2OTlpPkG1OlY1PTF7PD;hQi=>
Sf9 NVfJXmtnTnWwY4Tpc44h[XO|YYm= M2W2SWlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxKD1iMD6wNVIh|ryPLh?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
HeLa MmP6SpVv[3Srb36gZZN{[Xl? NGfROppKdmirYnn0bY9vKG:oIFHYMVc2ODNiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBRdGt|IHX4dJJme3OnZDDpckBJ\UyjIHPlcIx{KGK7IGfld5Rmem5iYnzveEwhUUN3MDC9JFAvODR7IN88UU4> MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzM{WyOFgoRjF5MUO1NlQ5RC:jPh?=
HeLa NVz0O2JXTnWwY4Tpc44h[XO|YYm= NV3jboN1SmmwZHnu[{Bi\m[rbnn0fUBnd3JiRF7BJIRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHN9IGLhcodmKGm|IEKwMVEzOCxiS3mgQUAxNjF{IN88UU4> NX[3bHRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
HeLa NX\t[FQ5TnWwY4Tpc44h[XO|YYm= MYnCbY5lcW6pIHHm[olvcXS7IH\vdkBRcG:|cHjheIllgWyrbn;zbZRwdCB|LXvpcoF{\SCrc3;sZZRm\CCocn;tJGhmVGFiY3XscJM8KFKjbnflJIl{KDJyLUGyNEwhU2liPTCwMlEzKM7:TT6= NUnZSYpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
A549 M2nsR2Z2dmO2aX;uJIF{e2G7 NVrkO|lTUW6qaXLpeIlwdiCxZjDQcIs{KGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4F{\WmwIIP1ZpN1emG2ZTDwbI9{eGixconsZZRqd25iYomgW4V{fGW{bjDicI91NCCLQ{WwJF0hOC5{MjFOwG0v NFnIOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GzOVI1QCd-MUexN|UzPDh:L3G+
A549 Mmj2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUj6N|k2PDhiaILz NH;5NpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBu\XSqb3SsJGlEPTBiPTCxNU41KM7:TT6= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ|MEi5OEc,OTh4M{C4PVQ9N2F-
GM00637 MVvGeY5kfGmxbjDhd5NigQ>? NG\xUoEyKHWP MYLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IGDsb|Mh\XiycnXzd4VlKGmwIHj1cYFvKEePMEC2N|ch[2WubIOgZZQhOSC3TTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyNUOgd4VzcW6nLUKwJJBpd3OyaH;yfYxifGmxbh?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF|NUK0PEc,OTdzM{WyOFg9N2F-
MDA-MB-231 MXXGeY5kfGmxbjDhd5NigQ>? MnPsNUB1dyBzMDD1US=> NYDEbnFNOjRiaILz NHHTW4dKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NGCzPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiyPFI5Pid-MkS4NlgzQDZ:L3G+
HeLa NH7zR2lHfW6ldHnvckBie3OjeR?= MYixNFAhdk1? NHnTXoYyOCCvaX7z M2jXV2lvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFN2N{OgZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OEC4OlUoRjNyM{iwPFY2RC:jPh?=
HeLa MYnGeY5kfGmxbjDhd5NigQ>? MkXXNVAxKG6P MmjlNVAhdWmwcx?= M4\UcmlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFR|MEigZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M1TKcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{iwPFY2Lz5|MEO4NFg3PTxxYU6=
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3 25344912
Immunofluorescence DNMT1 24001151
Growth inhibition assay Cell viability 25344912
体内研究 Wortmannin剂量为1mg/kg可抑移植瘤小鼠中SW1990的腹膜转移,无重量损失。[10] Wortmannin抑制在小鼠正常组织(肺,心脏和脑组织匀浆)及肿瘤组织中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在剂量为0.7 mg/kg时无死亡或急性毒性。与gemcitabine联合使用时,可大大增加细胞凋亡和抑制原位肿瘤生长,两种药物单独使用都无以上效果。[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[11]
  • Animal Models: 人胰腺癌细胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。
  • Dosages: 0.175, 0.35, 和0.7 mg/kg
  • Administration: 静脉注射

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O

5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.43
化学式

C23H24O8

CAS号 19545-26-7
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们